Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Rating) by 8.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,631 shares of the biotechnology company’s stock after selling 1,012 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Sarepta Therapeutics were worth $1,286,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SRPT. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth $91,000. Vanguard Capital Wealth Advisors acquired a new stake in Sarepta Therapeutics in the third quarter valued at $260,000. Naples Global Advisors LLC purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth about $221,000. Nkcfo LLC acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth about $85,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at about $233,000. Institutional investors and hedge funds own 87.31% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 858 shares of the firm’s stock in a transaction dated Thursday, November 17th. The shares were sold at an average price of $109.92, for a total value of $94,311.36. Following the completion of the sale, the director now owns 6,387 shares in the company, valued at $702,059.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.40% of the company’s stock.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $127.80 on Friday. The stock has a market capitalization of $11.22 billion, a price-to-earnings ratio of -15.57 and a beta of 1.04. The business’s 50 day moving average is $121.49 and its two-hundred day moving average is $110.05. Sarepta Therapeutics, Inc. has a 12-month low of $61.28 and a 12-month high of $134.08. The company has a current ratio of 4.36, a quick ratio of 3.99 and a debt-to-equity ratio of 3.58.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($2.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.21) by ($1.73). Sarepta Therapeutics had a negative return on equity of 97.37% and a negative net margin of 81.76%. The business had revenue of $230.30 million for the quarter, compared to analyst estimates of $234.55 million. During the same period in the prior year, the company earned ($0.60) EPS. The company’s revenue was up 21.6% on a year-over-year basis. Research analysts expect that Sarepta Therapeutics, Inc. will post -8.19 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Royal Bank of Canada lowered their price target on Sarepta Therapeutics from $193.00 to $190.00 and set an “outperform” rating for the company in a report on Thursday, November 3rd. Cowen lifted their price target on shares of Sarepta Therapeutics from $114.00 to $125.00 in a research note on Wednesday, January 11th. Robert W. Baird upped their price objective on shares of Sarepta Therapeutics from $110.00 to $152.00 in a research note on Thursday, November 3rd. Credit Suisse Group lifted their target price on Sarepta Therapeutics from $101.00 to $114.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 10th. Finally, StockNews.com started coverage on Sarepta Therapeutics in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $149.07.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

Featured Stories

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.